Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: Cytogenetic and JAK2V617F molecular remissions [5]

A. Tefferi, T. L. Lasho, R. A. Mesa, A. Pardanani, R. P. Ketterling, C. A. Hanson

Research output: Contribution to journalLetterpeer-review

95 Scopus citations

Fingerprint Dive into the research topics of 'Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: Cytogenetic and JAK2V617F molecular remissions [5]'. Together they form a unique fingerprint.